Home › B-Cell Leukemia
B-Cell Leukemia clinical trials recruiting in the U.S.
17 studies for B-Cell Leukemia are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX7 studies
- Washington, DC5 studies
- Dallas, TX5 studies
- Columbus, OH4 studies
- Portland, OR4 studies
- Spokane, WA3 studies
- Pittsburgh, PA3 studies
- Louisville, KY3 studies
- Edison, NJ3 studies
- San Diego, CA3 studies
- Chicago, IL3 studies
- Denver, CO3 studies
- Boston, MA3 studies
- New York City, NY3 studies
- Philadelphia, PA3 studies
- Charlotte, NC3 studies
- Clifton, NJ3 studies
By state
- California7 studies
- Colorado3 studies
- Florida3 studies
- Illinois4 studies
- Kansas3 studies
- Kentucky3 studies
- Maryland5 studies
- Massachusetts3 studies
- Minnesota3 studies
- New Jersey4 studies
- New York4 studies
- North Carolina5 studies
- Ohio7 studies
- Oregon4 studies
- Pennsylvania5 studies
- Texas12 studies
- Washington5 studies
Recently updated studies
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Sep 28, 2026 · NCT00923507Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RecruitingPhase 4
Ages 18 to 130 · All sexes · Updated Sep 24, 2026 · NCT06651970Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04728893Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
RecruitingPhase 1
Up to age 75 · All sexes · Updated Sep 16, 2026 · NCT06345027Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
RecruitingPhase 3
Ages 18 to 18 · All sexes · Updated Sep 8, 2026 · NCT07509151A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06564038Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
RecruitingPhase 1
12 Months – 25 Years · All sexes · Updated Sep 4, 2026 · NCT05010564Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RecruitingPhase 2
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05254743ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07342478A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06542250A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06708897CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
RecruitingPhase 1/2
Ages 3 to 39 · All sexes · Updated Jul 30, 2026 · NCT05442515The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
RecruitingObservational study
Ages 1 to 23 · All sexes · Updated Feb 25, 2026 · NCT07422337Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
RecruitingObservational study
All ages · All sexes · Updated Jan 22, 2026 · NCT06357754From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.